Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of eclitasertib in adults with moderate to severe ulcerative colitis
NL-OMON60888Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eclitasertib in autoimmune colitis (3 arms), sponsored by Sanofi. Primary endpoint: Clinical remission at Week 12 by modified Mayo score. Started Jan 2025; status: completed.
02
Drugs
eclitasertib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON60888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60888.